Activating mutations in the gene encoding BRAF are the most commonly identified
oncogenic abnormalities in papillary thyroid cancer. In vitro and in vivo models have …

1. ABSTRACT BRAF is a cytoplasmic serine-threonine protein kinasethat plays a critical role
in the MAPK signaling pathway. BRAF is the only member of the RAF family activated by …

BRAF, a cytoplasmic serine–threonine protein kinase, plays a critical role in cell signaling as
an activator within the mitogen-activated protein kinase (MAPK) pathway. The most common …

Purpose: Oncogenic conversion of BRAF occurs in∼ 44% of papillary thyroid carcinomas
and 24% of anaplastic thyroid carcinomas. In papillary thyroid carcinomas, this mutation is …

B-Raf is an important mediator of cell proliferation and survival signals transduced via the
Ras-Raf-MEK-ERK cascade. BRAF mutations have been detected in several tumors …

Background Thyroid carcinomas show a high prevalence of mutations in the oncogene
BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The …

Mutations in the BRAF gene are highly prevalent in thyroid cancer. However, the response
rate of thyroid tumors to BRAF‐directed therapies has been mixed. Increasingly …

Genetic alteration is the driving force for thyroid tumorigenesis and progression, based upon
which novel approaches to the management of thyroid cancer can be developed. A recent …

Background: Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the
thyroid gland, accounting for 74–80% of all thyroid cancers. The 1799T> A transversion is an …

An activating mutation in the BRAF gene is the most common genetic alteration in papillary
thyroid carcinomas (PTCs). The mutation in PTCs is almost a c. 1799T> A transversion …